All In Biotech

Drug Trial Radar · NCT00648323

Evaluation Of The Efficacy And Safety Of The Doxasozin Gastrointestinal Therapeutic System (GITS) In Patients With Prostate Enlargement

A Prospective, Open-Labeled Trial of the Safety and Efficacy of Doxazosin GITS in Patients With Benign Prostate Hyperplasia

Last checked: Nov 20, 2026Latest source record: Jan 29, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

80

Actual

Start

Nov 2003

Primary completion

Not stated

Study completion Jan 2005

Sponsor

Sponsor type
Industry
First posted
Apr 1, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
Male only, from 50 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objectives were to determine the efficacy and safety of the GITS formulation of Doxazosin in Taiwanese patients with prostate enlargement.

Conditions

  • Prostate

Interventions

  • Doxazosin mysylate GITSDrug

    Subjects initiated on 4 mg doxazosin GITS once daily at Visit 1 for four weeks. At Visit 2 (Week 4) increased to 8 mg Doxazosin GITS if efficacy response criteria not met.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in the maximum urinary flow rate (Qmax) from baselineTime frame: 8 weeks
  2. Change in the International Prostate Symptom Score (IPSS) total score from baselineTime frame: 8 weeks

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Pfizer Investigational Site

    Kaohsiung City, Taiwan

  • Pfizer Investigational Site

    Taichung, Taiwan

  • Pfizer Investigational Site

    Taipei, Taiwan

  • Pfizer Investigational Site

    Taoyuan, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.